Kidney Effects of Levothyroxine in Adults with Chronic Kidney Disease and Subclinical Hypothyroidism: A Systematic Review of Randomized Trials
SN Comprehensive Clinical Medicine · 11.11.2026 · 8 (1)
DOI: 10.1007/s42399-026-02869-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 11.11.2026. Verfasst von Srijita Chatterjee und 4 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Purpose
The clinical benefit of levothyroxine (LT4) therapy in patients with chronic kidney disease (CKD) and subclinical hypothyroidism (SCH) remains uncertain. SCH is common in CKD and has been associated with adverse renal outcomes. While LT4 is the standard treatment for overt hypothyroidism, its role in this high-risk group, particularly regarding renal outcomes and thyroid parameters, remains unclear. We aimed to systematically review randomized controlled trial (RCT) evidence on the effects of LT4 therapy on renal and thyroid-related outcomes in adults with CKD and SCH.
Methods
We conducted a systematic review of randomized controlled trials( RCTs) comparing LT4 with placebo in adults with CKD predominantly having type 2 diabetes and SCH. PubMed, Embase, and the Cochrane Library were searched for relevant studies. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool .Findings were synthesized narratively because of the limited number of eligible trials and clinical and methodological heterogeneity. Primary outcomes were serum creatinine and estimated glomerular filtration rate (eGFR).Secondary outcomes included urinary protein excretion, urinary albumin excretion rate (UAER), thyroid function parameters, and blood pressure.
Results
Three RCTs analyzing 235 participants (121 levothyroxine; 114 placebo) were included; 96.6% of them had type 2 diabetes mellitus.LT4 was associated with reductions in thyroid-stimulating hormone (TSH), whereas changes in free triiodothyronine (FT3) and free thyroxine (FT4) varied across trials. Findings for eGFR and serum creatinine did not demonstrate a consistent between-group benefit. Significant between-group differences were reported for urinary protein excretion and UAER, with findings favoring LT4 treatment across all three trials. No significant between-group differences in blood pressure were reported.
Conclusion
In the predominantly diabetic CKD population studied, LT4 was associated with reductions in TSH, whereas its effects on eGFR and serum creatinine were inconsistent. Although some trials reported favorable changes with LT4 for urinary albumin and protein excretion, their clinical relevance remains uncertain. These findings warrant cautious interpretation given the short follow-up periods (12–48 weeks) and reliance on biochemical parameters and renal surrogate markers, which preclude firm conclusions regarding the durability of these effects or their implications for long-term CKD progression.
Zitieren
APA
Chatterjee, S., Taha, K., Ubaldo, H. B., Chintharala, K., & Sa, J. R. (2026). Kidney Effects of Levothyroxine in Adults with Chronic Kidney Disease and Subclinical Hypothyroidism: A Systematic Review of Randomized Trials. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02869-9
Vancouver
Chatterjee S, Taha K, Ubaldo HB, Chintharala K, Sa JR. Kidney Effects of Levothyroxine in Adults with Chronic Kidney Disease and Subclinical Hypothyroidism: A Systematic Review of Randomized Trials. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02869-9
BibTeX
@article{Chatterjee2026,
author = {Chatterjee, Srijita and Taha, Khalid and Ubaldo, Helena Beckhäuser and Chintharala, Karthik and Sa, João Roberto},
title = {Kidney Effects of Levothyroxine in Adults with Chronic Kidney Disease and Subclinical Hypothyroidism: A Systematic Review of Randomized Trials},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02869-9}
}
EUVIMED